214 related articles for article (PubMed ID: 17581612)
21. Safflower seed extract inhibits osteoclast differentiation by suppression of the p38 mitogen-activated protein kinase and IκB kinase activity.
Moon HJ; Kim EK; Nam YS; Kim JH; Ko WK; Lee JM; Lee CH; Jang JB; Lee KS; Kwon IK
Phytother Res; 2012 Nov; 26(11):1648-55. PubMed ID: 22389167
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
23. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
[TBL] [Abstract][Full Text] [Related]
24. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
25. TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells.
Yen ML; Tsai HF; Wu YY; Hwa HL; Lee BH; Hsu PN
Mol Immunol; 2008 Apr; 45(8):2205-13. PubMed ID: 18206242
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
[TBL] [Abstract][Full Text] [Related]
27. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4.
Chang EJ; Kim HJ; Ha J; Kim HJ; Ryu J; Park KH; Kim UH; Lee ZH; Kim HM; Fisher DE; Kim HH
J Cell Sci; 2007 Jan; 120(Pt 1):166-76. PubMed ID: 17164294
[TBL] [Abstract][Full Text] [Related]
29. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
30. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells.
Mozar A; Haren N; Chasseraud M; Louvet L; Mazière C; Wattel A; Mentaverri R; Morlière P; Kamel S; Brazier M; Mazière JC; Massy ZA
J Cell Physiol; 2008 Apr; 215(1):47-54. PubMed ID: 17894387
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
[TBL] [Abstract][Full Text] [Related]
32. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
[TBL] [Abstract][Full Text] [Related]
33. Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways.
Ma X; Liu Y; Zhang Y; Yu X; Wang W; Zhao D
Biochem Biophys Res Commun; 2014 Mar; 445(2):282-8. PubMed ID: 24491533
[TBL] [Abstract][Full Text] [Related]
34. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
[TBL] [Abstract][Full Text] [Related]
35. Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-κB and ERK.
Ang E; Liu Q; Qi M; Liu HG; Yang X; Chen H; Zheng MH; Xu J
J Cell Biochem; 2011 Jan; 112(1):89-97. PubMed ID: 20683903
[TBL] [Abstract][Full Text] [Related]
36. Momordin I, an inhibitor of AP-1, suppressed osteoclastogenesis through inhibition of NF-kappaB and AP-1 and also reduced osteoclast activity and survival.
Hwang YH; Lee JW; Hahm ER; Jung KC; Lee JH; Park CH; Rhee HS; Ryu JM; Kim HK; Yang CH
Biochem Biophys Res Commun; 2005 Nov; 337(3):815-23. PubMed ID: 16213465
[TBL] [Abstract][Full Text] [Related]
37. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
38. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function.
Zavrski I; Krebbel H; Wildemann B; Heider U; Kaiser M; Possinger K; Sezer O
Biochem Biophys Res Commun; 2005 Jul; 333(1):200-5. PubMed ID: 15936724
[TBL] [Abstract][Full Text] [Related]
39. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.
Park B
Biochimie; 2014 Oct; 105():129-36. PubMed ID: 25047443
[TBL] [Abstract][Full Text] [Related]
40. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
